A phase IA/IB, two arm, multi-center, open-label, dose escalation study of oral LBH589 [panobinostat] alone and in combination with IV docetaxel and oral prednisone in hormone refractory prostate cancer (HPRC)

Trial Profile

A phase IA/IB, two arm, multi-center, open-label, dose escalation study of oral LBH589 [panobinostat] alone and in combination with IV docetaxel and oral prednisone in hormone refractory prostate cancer (HPRC)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Docetaxel; Panobinostat; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top